The drugmaker plans to add two new production lines to the plant. One is slated to be done by fall, and the other by early 2022. The expansion will make it easier to produce Moderna’s COVID-19 vaccine and booster shots, should they become necessary to increase waning immunity levels or protect against coronavirus variants in coming years.
Moderna is also expanding its manufacturing capacity internationally, seeking to roughly triple its annual global production to about 3 billion vaccine doses in 2022.
